Improving efficacy and toxicity reporting - and treatment insights from an oncologist patient

CURB phase II trial: Tumour burden predicts survival after SBRT in NSCLC oligoprogression

WCLC 2025: Latest in EGFR positive NSCLC

Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line maintenance

The hidden biology of addiction and cancer

Key insights from lung cancer research at ASCO 2025

Molecular assay may help identify NSCLC patients who could benefit from adjuvant chemotherapy

Making immune check point inhibitors for lung cancer cost-effective in LMICs

ASCO 2025: Latest in EGFR positive NSCLC

ELCC 2025: Latest in EGFR positive NSCLC

Adding durvalumab to neoadjuvant chemotherapy maintains quality of life in resectable NSCLC

Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA high PD-L1 expression NSCLC